Share: Facebook Twitter LinkedIn
Activity Provided By:


A BRIGHTE New Option: Fostemsavir for Drug Resistant HIV

Access Activity

Overview / Abstract:

Combination antiretroviral therapy has changed the trajectory of outcomes for people living with HIV by dramatically reducing morbidity and mortality from the virus. While first line therapeutic options are effective disease management strategies for most patients, treatment options are quite limited for those who have developed multidrug resistant HIV. This application-based continuing pharmacy education activity will provide a ‘journal club format’ discussion for pharmacists and student pharmacists to review the findings of the BRIGHTE study recently published in the New England Journal of Medicine. Join us to discuss the phase 3 clinical study evaluating the performance of the novel agent fostemsavir in patients with multidrug resistant HIV.


Jun 10, 2023


Pharmacy CPE


Online, Webinar / Webcast / Video



Credits / Hours




Presenters / Authors / Faculty

John Zeuli, PharmD, BCPS-AQ ID, AAHIVP
Infectious Disease Pharmacist
Mayo Clinic
Rochester, MN

Keywords / Search Terms

CEI Impact live, human immunodeficiency virus, litl, l2l, login to learn, log-in to learn, journal club, hiv, hiv therapy, brighte, fostemsavir, foste, bright, drug resistant, drug resistant hiv, drug-resist, drug resist, clinical trial, multidrug, multi-drug, multidrug-resistant hiv, multidrug-resistant, antiretroviral, antiretroviral therapy, hvi, antiretroviral agents

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map